These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 15620483

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy.
    Bettinotti MP, Kim CJ, Lee KH, Roden M, Cormier JN, Panelli M, Parker KK, Marincola FM.
    J Immunol; 1998 Jul 15; 161(2):877-89. PubMed ID: 9670966
    [Abstract] [Full Text] [Related]

  • 3. Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes.
    Ishioka GY, Fikes J, Hermanson G, Livingston B, Crimi C, Qin M, del Guercio MF, Oseroff C, Dahlberg C, Alexander J, Chesnut RW, Sette A.
    J Immunol; 1999 Apr 01; 162(7):3915-25. PubMed ID: 10201910
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Evaluation of antitumor immunity efficacy of epitope-based vaccine with B16 cell line coexpressing HLA-A2/H-2kb and CTL multiepitope in HLA transgenic mice.
    Song S, Wang F, He X, He Y, Li D, Sun S.
    Vaccine; 2007 Jun 15; 25(25):4853-60. PubMed ID: 17418455
    [Abstract] [Full Text] [Related]

  • 6. Induction of multiepitopic and long-lasting immune responses against tumour antigens by immunization with peptides, DNA and recombinant adenoviruses expressing minigenes.
    Durántez M, López-Vázquez AB, de Cerio AL, Huarte E, Casares N, Prieto J, Borrás-Cuesta F, Lasarte JJ, Sarobe P.
    Scand J Immunol; 2009 Feb 15; 69(2):80-9. PubMed ID: 19144076
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses.
    Adotévi O, Mollier K, Neuveut C, Cardinaud S, Boulanger E, Mignen B, Fridman WH, Zanetti M, Charneau P, Tartour E, Lemonnier F, Langlade-Demoyen P.
    Clin Cancer Res; 2006 May 15; 12(10):3158-67. PubMed ID: 16707616
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen.
    Terasawa H, Tsang KY, Gulley J, Arlen P, Schlom J.
    Clin Cancer Res; 2002 Jan 15; 8(1):41-53. PubMed ID: 11801539
    [Abstract] [Full Text] [Related]

  • 11. Recognition of HLA-A2-restricted mammaglobin-A-derived epitopes by CD8+ cytotoxic T lymphocytes from breast cancer patients.
    Jaramillo A, Narayanan K, Campbell LG, Benshoff ND, Lybarger L, Hansen TH, Fleming TP, Dietz JR, Mohanakumar T.
    Breast Cancer Res Treat; 2004 Nov 15; 88(1):29-41. PubMed ID: 15538043
    [Abstract] [Full Text] [Related]

  • 12. Specific antitumor immune response induced by a novel DNA vaccine composed of multiple CTL and T helper cell epitopes of prostate cancer associated antigens.
    Qin H, Zhou C, Wang D, Ma W, Liang X, Lin C, Zhang Y, Zhang S.
    Immunol Lett; 2005 Jun 15; 99(1):85-93. PubMed ID: 15894116
    [Abstract] [Full Text] [Related]

  • 13. Vaccination strategy determines the emergence and dominance of CD8+ T-cell epitopes in a FVB/N rat HER-2/neu mouse model of breast cancer.
    Singh R, Paterson Y.
    Cancer Res; 2006 Aug 01; 66(15):7748-57. PubMed ID: 16885378
    [Abstract] [Full Text] [Related]

  • 14. HLA class I - associated immunodominance affects CTL responsiveness to an ESO recombinant protein tumor antigen vaccine.
    Bioley G, Guillaume P, Luescher I, Yeh A, Dupont B, Bhardwaj N, Mears G, Old LJ, Valmori D, Ayyoub M.
    Clin Cancer Res; 2009 Jan 01; 15(1):299-306. PubMed ID: 19118058
    [Abstract] [Full Text] [Related]

  • 15. Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-expressing Tumors.
    Bioley G, Guillaume P, Luescher I, Bhardwaj N, Mears G, Old L, Valmori D, Ayyoub M.
    J Immunother; 2009 Jan 01; 32(2):161-8. PubMed ID: 19238015
    [Abstract] [Full Text] [Related]

  • 16. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
    Bondurant KL, Crew MD, Santin AD, O'Brien TJ, Cannon MJ.
    Clin Cancer Res; 2005 May 01; 11(9):3446-54. PubMed ID: 15867247
    [Abstract] [Full Text] [Related]

  • 17. A novel mouse model for evaluation and prediction of HLA-A2-restricted CEA cancer vaccine responses.
    Conforti A, Peruzzi D, Giannetti P, Biondo A, Ciliberto G, La Monica N, Aurisicchio L.
    J Immunother; 2009 Sep 01; 32(7):744-54. PubMed ID: 19561534
    [Abstract] [Full Text] [Related]

  • 18. Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments.
    Held G, Matsuo M, Epel M, Gnjatic S, Ritter G, Lee SY, Tai TY, Cohen CJ, Old LJ, Pfreundschuh M, Reiter Y, Hoogenboom HR, Renner C.
    Eur J Immunol; 2004 Oct 01; 34(10):2919-29. PubMed ID: 15368308
    [Abstract] [Full Text] [Related]

  • 19. Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses.
    Eguchi J, Hatano M, Nishimura F, Zhu X, Dusak JE, Sato H, Pollack IF, Storkus WJ, Okada H.
    Cancer Res; 2006 Jun 01; 66(11):5883-91. PubMed ID: 16740728
    [Abstract] [Full Text] [Related]

  • 20. The use of HLA class I tetramers to design a vaccination strategy for melanoma patients.
    Palmowski M, Salio M, Dunbar RP, Cerundolo V.
    Immunol Rev; 2002 Oct 01; 188():155-63. PubMed ID: 12445289
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.